Manuela Caruso

Associate Professor of GENERAL AND SUBSPECIALTY PAEDIATRICS [MED/38]

Prof. Manuela Caruso was born in Catania (Italy) on November 15,1959.
She got her medical degree at the University of Catania Medical School in 1983.She trained in Pediatrics at the Department of Pediatrics, University of Catania and became Pediatric Specialist in 1987.
She trained in Pediatric Endocrinolgy at the Development Endocrinology Branch, National Institute of Child Health and Human Develpment, NIH (Bethesda,MD,USA).

Positions:
-Jan-Dec 1984 "guest worker", Development Endocrinology Branch, National Institute of Child Health and Human Development, NIH (Bethesda, MD, USA)
-Jan 1985-Dec 1986 Visiting Fellow (Fogarty Fellowship) Development Endocrinology Branch, National Institute of Child Health and Human Development,NIH (Bethesda,MD,USA)
-1988-1992 Research Fellow, Department of Pediatrics, University of Catania
-From November 1984 Associate Professor of Pediatrics, Department of Pediatrics, University of Catania
-From November 1984 Chief of Pediatric Endocrinology and Diabetology, Department of Pediat-rics, University of Catania
She is currently teaching Pediatrics at the University of Catania Medical School and Pediatric Endocrinology in the Schools of Pediatrics, Pediatric Neuropsychiatry, Pediatric Surgery.

She is the author of more than 200 pubblications on national and international journals. 
She is member of the Italian Society of Pediatrics (SIP),Italian Society of Endocrinlogy and Dia-betology (ISPED),Italian Society of Adolescence Medicine (SIMA), European Society of Pediat-ric Endocrinology (ESPE).
She has participated to several national and international clinical trials.
She has been revisor for the following scientific journals: Italian Journal of  Pediatrics;Acta Haematologica; The Journal of Pediatric Endocrinology and Metabolism; Journal of Endocr-nological Investigation; Hormone Research in Pediatrics; European Journal of Endocrinology.

 

VIEW THE PUBLICATIONS
N.B. the number of publications can affect the loading time of the information
VIEW THE COURSES FROM THE A.Y. 2022/2023 TO THE PRESENT

Academic Year 2021/2022


Academic Year 2020/2021


Academic Year 2019/2020


Academic Year 2018/2019


Academic Year 2017/2018


Academic Year 2016/2017


Academic Year 2015/2016

Causes and treatment of growth defects

Endocrine complications in chronic diseases

Diabetes in child-hood (Diabetes Mellitus Type 1

Neonatal diabetes Mellitus)

Genotype-fenotype correlation in Congenital Adrenal Hyperplasia

Congenital Hyperinsulinism of Infancy

 

KEYWORDS:
GROWTH -  DEVELOPMENT -  PUBERTY -  AUXOLOGY -  GH -  INSULIN -  DIABETES -  THYROID -  ADRENAL GLAND - CHRONIC DISEASES -  SYNDROMES -  BONE DYSPLASIA -  GENETICS 

 

 

Clinical Trials:

  • Protocollo CTN 93-8122-008 “Genotropin nei bambini con ritardo di crescita intrauterino. Studio aperto, multicentrico, comparativo,randomizzato, nazionale.”
  • Protocollo TRN 90111-12 “An open-labelled multicentre study on growth and safety with long-term treatment of recombinant human Insulin-like Growth Factor I (k 3141)  to children with Laron type dwarfism and GH-gene deletion”.
  • Protocollo GHLIQUID-188 “An open randomised multicentre, 2-period crossover trial evaluating in GHD children the acceptance of the new liquid Norditropin Simplexx versus the freeze-dried Norditropin 4 I.U.
  • Protocollo SP 553 “A multicenter, multinational,open label, randomized, parallel group trial of the efficacy and safety of two dosage regimens of Nutropin Depot in comparison with Nutropin AQ, studied over a duration of 12 months in children with growth failure due to growth hormone deficiency”
  • Protocollo BR-IT-GDFT “The Genetics and Neuroendocrinology in children with GHD. A part of GeNeSIS
  • Protocollo RHGH00312001 “Studio multicentrico in aperto di fase III in soggetti con deficit isolato dell’ormone della crescita: valutazione del profilo psico-affettivo-cognitivo e delle sue variazioni a seguito di trattamento con ormone della crescita
  • Protocollo B9R-IT-GDFU “Efficacia e sicurezza di un dosaggio alto confrontato al dosaggio standard di Humatrope in bambini/e con deficit di GH nello stadio precoce di pubertà
  • Protocollo Optima 2 79 58035 700  “Phase III B , international, single group, pen study to define an optimal monitoring of IGF-1 in children treated with NutropinAq using a novel capillary blood collection method”
  • Protocollo B9R-EW-GDF (a)(12) “The Genetics and Neuroendocrinology of Short Stature International Study”
  • Studio clinico A6281287 (Eudract n. 2007-003949-32) “Studio multicentrico, randomizzato, a due bracci e della durata di due anni, sul trattamento con genotropin in bambini giovanissimi nati piccolo per l’età gestazionale: studio EGN (early growth and neurodeve-lopment)”
  • Protocollo EMR701048_507  “Easypod adherence in children with growth disorders treated with rhGH
  • Studio clinico EMR20001104_10-PREDICT: Studio di validazione farmacogenetica PREDICT (EUDRACT 2011-000460-10)
  • Studio Clinico  EMR200104_529 : “Studio osservazionale multicentrico, nazionale per valutare l’Aderenza e gl Esiti a lungo termine della terapia in soggetti pediatrici che utilizzano easypod, dispositivo elettromeccanico per la somministrazione dell’ormone della crescita-ECOS”


Revisor for the following scientific journals:

Italian Journal of  Pediatrics;
Acta Haematologica;
The Journal of Pediatric Endocrinology and Metabolism;
Journal of Endocrinological Investigation;
Hormone Research in Pediatrics;
European Journal of Endocrinology.